quadrivalent influenza vaccine (KBP-V001) / British American Tobacco - LARVOL DELTA

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - P1; N=120; Completed; Sponsor: Kentucky BioProcessing, Inc.; Active, not recruiting ➔ Completed; Trial primary completion date: Aug 2021 ➔ Feb 2021

Clinical • Trial completion • Trial primary completion date • Infectious Disease • Respiratory Diseases

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - P1; N=120; Active, not recruiting; Sponsor: Kentucky BioProcessing, Inc.; Trial completion date: Jun 2021 ➔ Sep 2021

Clinical • Trial completion date • Infectious Disease • Respiratory Diseases

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - P1; N=120; Active, not recruiting; Sponsor: Kentucky BioProcessing, Inc.; Trial primary completion date: Mar 2021 ➔ May 2021

Clinical • Trial primary completion date • Infectious Disease • Respiratory Diseases

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - P1; N=120; Active, not recruiting; Sponsor: Kentucky BioProcessing, Inc.; Recruiting ➔ Active, not recruiting; Trial completion date: Feb 2021 ➔ Jun 2021

Clinical • Enrollment closed • Trial completion date • Infectious Disease • Respiratory Diseases

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - P1; N=120; Recruiting; Sponsor: Kentucky BioProcessing, Inc.; Not yet recruiting ➔ Recruiting

Clinical • Enrollment open • Infectious Disease

Study to Evaluate the Safety and Immunogenicity of KBP-V001 Quadrivalent Influenza Vaccine in Healthy Adults (clinicaltrials.gov) - P1; N=120; Not yet recruiting; Sponsor: Kentucky BioProcessing, Inc.

Clinical • New P1 trial • Infectious Disease